Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BG Medicine, Inc. (BGMD)

Other OTC - Other OTC Delayed Price. Currency in USD
0.00010.0000 (0.00%)
At close: 09:31AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0001
Open0.0001
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0001 - 0.0001
52 Week Range0.0001 - 0.0100
Volume500
Avg. Volume16
Market Cap545,969
Beta (5Y Monthly)77.63
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BGMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BG MEDICINE INC
    Analyst Report: Quest Diagnostics IncorporatedQuest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • We're sorry we weren't able to find anything about this topic.

Advertisement
Advertisement